Rosuvastatin20mg Sandoz အဆီကျဆေး

Rosuvastatin Ca

Indications/Uses

Adjunct to diet in primary hypercholesterolaemia & mixed dyslipidaemia (type IIb) when response to diet or nonpharmacological treatments (eg, exercise, wt reduction) are inadequate. Adjunct to diet & other lipid-lowering treatments (eg, LDL apheresis) or if such treatments are not appropriate in homozygous familial hypercholesterolaemia. Prevention of CV events & major CV events in patients who are estimated to have a high risk for a 1st CV event as an adjunct to correction of other risk factors. Slow or delay the progression of atherosclerosis.

Dosage/Direction for Use

Primary hypercholesterolaemia or mixed dyslipidaemia (type IIb) Initially 5-10 mg once daily. May be adjusted after 4 wk if needed. Patients w/ severe hypercholesterolaemia at high CV risk Max dose: 40 mg once daily. Homozygous familial hypercholesterolaemia Initial dose: 20 mg once daily. Max dose: 40 mg once daily.

Administration

May be taken with or without food.

Contraindications

Hypersensitivity. Active liver disease or unexplained persistent elevations of serum transaminases exceeding 3 times the upper limit of normal. Severe renal impairment (CrCl <30 mL/min); myopathy; concomitant use of ciclosporin. Pregnancy & lactation.

Special Precautions

Proteinuria. Skeletal muscle effects eg, uncomplicated myalgia, myopathy & rarely rhabdomyolysis. Predisposing factors for rhabdomyolysis or myopathy eg, renal impairment, hypothyroidism, personal or family history of muscular disorders, previous history of muscular toxicity w/ another HMG-CoA reductase inhibitor or fibrate, alcohol abuse & age >70 yr. Acute, serious conditions suggestive of myopathy or predisposing to the development of renal failure secondary to rhabdomyolysis. Excessive alcohol consumption & history of liver disease. Childn.

Adverse Reactions

DM; headache, dizziness; constipation, nausea, abdominal pain; myalgia; asthenia.

Drug Interactions

Ciclosporin, vit K antagonists, PIs, antacid, erythromycin, OC/hormone-replacement therapy.

MIMS Class

Dyslipidaemic Agents